Navigation Links
Light powered platinum more targeted and 80 times more powerful than similar cancer treatments
Date:12/21/2007

Researchers from the Universities of Warwick, Edinburgh, Dundee and the Czech Republics Institute of Biophysics have discovered a new light-activated platinum-based compound that is up to 80 times more powerful than other platinum-based anti-cancer drugs and which can use light activation to kill cancer cells in much more targeted way than similar treatments.

The platinum-based compound known as trans, trans, trans- [Pt(N3)2(OH)2(NH3)(py)], or a light activated PtIV complex, is highly stable and non-toxic if left in the dark but if light falls upon it becomes much less stable and highly toxic to cancer cells. In fact it is between 13 and 80 times more toxic (depending on how and on which cells it is used) to cancer cells than the current platinum based anti-cancer drug Cisplatin. Moreover it kills the cells by a different mechanism of action, so it can also kill cisplatin-resistant cells.

Professor Peter Sadler, Chairman of the Chemistry Department of the University of Warwick, who led the research project said:

Light activation provides its massive toxic power and also allows treatment to be targeted much more accurately against cancer cells.

The compound could be used in particular to treat surface cancers. Patients could be treated in a darkened environment with light directed specifically at cancer cells containing the compound activating the compounds toxicity and killing those cells. Normal cells exposed to the compound would be protected by keeping the patient in darkness until the compound has passed through and out of the patient.

The new light activated PtIV complex is also more efficient in its toxic action on cancer cells in that, unlike other compounds currently used in photodynamic therapy, it does not require the presence of significant amounts of oxygen within a cancer cell to become toxic. Cancer cells tend to have less oxygen present than normal cells.

Although this work is in its early stages, the researches are hopeful that, in a few years time, the new platinum compound could be used in a new type of photoactivated chemotherapy for cancer.


'/>"/>

Contact: Peter Dunn
p.j.dunn@warwick.ac.uk
44-077-676-55860
University of Warwick
Source:Eurekalert

Related medicine news :

1. Stanford study highlights cost-effective method of lowering heart disease risks
2. Study shines more light on benefit of vitamin D in fighting cancer
3. Bacteria See the Light
4. Quantum light beams good for fast technology
5. Free will takes flight: how our brains respond to an approaching menace
6. New MRI finding sheds light on multiple sclerosis disease progressio
7. RA Drugs Linked to Slight Skin Cancer Risk
8. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
9. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
10. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
11. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... ... Floundering on New Year’s resolutions? Need an excuse to get back on track? ... Apple Association agrees and recommends starting each day with apples, a habit proven ... , The U.S. Apple Association – which represents apple growers and producers nationwide – ...
(Date:1/17/2017)... ... January 17, 2017 , ... In the crowded ... is a stand-out company for several differences from other mainstream brands. , ... demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows them ...
(Date:1/17/2017)... ... January 17, 2017 , ... SunView Software’s Service Smart Technology has been selected ... , Each year, Pink Elephant recognizes a new product or service developed ... specific business problem or opportunity. The award highlights original innovations that were released in ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... well as Palm Desert, is opening a new office in San Clemente, California ... magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling with major depression. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s fastest ... practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of the ... to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD and ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... China,s National Regulatory Authority Chinese Food and Drug ... Dynavax Flanders Institute Food and Drug Administration ... Gavi Alliance Glaxo Smith Klein ... Service Bureau, Japan Immune Targeting Systems ... Jenner Institute, University of oxford Johnson & Johnson ...
(Date:1/17/2017)... -- Research and Markets has announced the addition of ... to their offering. ... The global artificial pancreas devices system market to grow at ... Artificial Pancreas Devices System Market 2016-2020, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:1/17/2017)... Paragon Bioservices received a multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) ... variety of National Institute of Allergy and ... The IDIQ mechanism will allow Paragon to compete ... up to $159 million. Paragon Bioservices, ... of biopharmaceuticals, is one of four awardees to ...
Breaking Medicine Technology: